XBiotech announces upcoming phase 2 clinical studies in dermatology
XBiotech announced it would evaluate a new subcutaneous formulation of the Company’s True Human™ monoclonal antibody, MABp1, in two separate Phase 2, open label, dose escalation studies in patients with moderate to severe Atopic Dermatitis and Hidradenitis Suppurativa. April 16, 2018